Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects
NCT ID: NCT02807233
Last Updated: 2019-08-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
115 participants
OBSERVATIONAL
2016-07-31
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
NCT00444873
Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT00499993
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00701363
Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
NCT00517491
Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
NCT00627796
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with acromegaly
* Receiving treatment with ATG 120 mg at extended dosing intervals (\> 4 weeks) for at least six months before the study visit.
* Assay data (blood GH and IGF-1 levels) from immediately before the study visit (performed at least six months after starting the treatment) is available.
* Able to sign the informed consent form for study participation.
Exclusion Criteria
* Active participation in another clinical study.
* Physical or mental disorders that, in the investigator's opinion, could affect their ability to sign the informed consent form.
* Pregnancy or breastfeeding for female patients.
* No data in their medical records on the treatment start date for ATG 120 mg at extended dosing intervals or on changes to the schedule of administration over the last six months.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital de Santa Maria
Lisbon, , Portugal
Centro Hospitalar Sao Jöao
Porto, , Portugal
Hospital Univ. Nuestra Sra. Candelaria
Santa Cruz, Tenerife, Spain
Complejo Hospitalario Univ. A Coruña
A Coruña, , Spain
Hospital Univ. Príncipe de Asturias
Alcalá de Henares, , Spain
Hospital General Univ. de Alicante
Alicante, , Spain
Hospital Univ. La Ribera
Alzira, , Spain
Hospital Infanta Cristina
Badajoz, , Spain
Hospital Cruces
Barakaldo, , Spain
Hospital Puerta del Mar
Cadiz, , Spain
Hospital Ciudad Real
Ciudad Real, , Spain
Hospital Reina Sofía
Córdoba, , Spain
Hospital de Getafe
Getafe, , Spain
Hospital Univ. Girona Dr. Josep Trueta
Girona, , Spain
Hospital de Jaén
Jaén, , Spain
Hospital Bellvitge
L'Hospitalet de Llobregat, , Spain
Hospital Univ. León
León, , Spain
Hospital Arnau de Vilanova
Lleida, , Spain
Hospital La Princesa
Madrid, , Spain
Hospital Gregorio Marañón
Madrid, , Spain
Hospital La Paz
Madrid, , Spain
Hospital Univv. La Paz
Madrid, , Spain
Hospital Puerta del Hierro
Madrid, , Spain
Hospital Civil de Málaga
Málaga, , Spain
Hospital Virgen de la Victoria
Málaga, , Spain
Hospital Univ. Central de Asturias
Oviedo, , Spain
Hospital Univ. Son Espases
Palma, , Spain
Corporacio Sanitaria Parc Tauli
Sabadell, , Spain
Hospital Infanta Sofía
San Sebastián de los Reyes, , Spain
Hospital Clínico Univ. Santiago
Santiago de Compostela, , Spain
Hospital Virgen del Rocío
Seville, , Spain
Hospital Univ. Alava
Terrassa, , Spain
Hospital Univ. Mutua de Terrassa
Terrassa, , Spain
Hospital Obispo Polanco
Teruel, , Spain
Hospital Virgen de la Salud
Toledo, , Spain
Hospital Clínico de Valencia
Valencia, , Spain
Hospital Univ. La Fe
Valencia, , Spain
Hospital Clínico Univ. Valladolid
Valladolid, , Spain
Hospital Miguel Servet
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IPS-SOM-2015-01
Identifier Type: OTHER
Identifier Source: secondary_id
A-ES-52030-352
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.